JPWO2019226514A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019226514A5 JPWO2019226514A5 JP2020564841A JP2020564841A JPWO2019226514A5 JP WO2019226514 A5 JPWO2019226514 A5 JP WO2019226514A5 JP 2020564841 A JP2020564841 A JP 2020564841A JP 2020564841 A JP2020564841 A JP 2020564841A JP WO2019226514 A5 JPWO2019226514 A5 JP WO2019226514A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- gene
- adenocarcinoma
- treatment
- expression level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 201000011510 cancer Diseases 0.000 claims 11
- 230000004547 gene signature Effects 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 11
- 238000009169 immunotherapy Methods 0.000 claims 6
- 239000012472 biological sample Substances 0.000 claims 5
- 208000009956 adenocarcinoma Diseases 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 102100021186 Granulysin Human genes 0.000 claims 2
- 102100030386 Granzyme A Human genes 0.000 claims 2
- 102100030385 Granzyme B Human genes 0.000 claims 2
- 102100038393 Granzyme H Human genes 0.000 claims 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 2
- 101001040751 Homo sapiens Granulysin Proteins 0.000 claims 2
- 101001009599 Homo sapiens Granzyme A Proteins 0.000 claims 2
- 101001009603 Homo sapiens Granzyme B Proteins 0.000 claims 2
- 101001033000 Homo sapiens Granzyme H Proteins 0.000 claims 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 2
- 101000987581 Homo sapiens Perforin-1 Proteins 0.000 claims 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 2
- 102000017578 LAG3 Human genes 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 102100028467 Perforin-1 Human genes 0.000 claims 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 claims 1
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 claims 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102100038077 CD226 antigen Human genes 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 102100038078 CD276 antigen Human genes 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 102100025221 CD70 antigen Human genes 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 claims 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 1
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 1
- -1 ICOS Proteins 0.000 claims 1
- 108020003285 Isocitrate lyase Proteins 0.000 claims 1
- 102000002698 KIR Receptors Human genes 0.000 claims 1
- 108010043610 KIR Receptors Proteins 0.000 claims 1
- 101150069255 KLRC1 gene Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 claims 1
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 claims 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 239000012270 PD-1 inhibitor Substances 0.000 claims 1
- 239000012668 PD-1-inhibitor Substances 0.000 claims 1
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 1
- 239000012272 PD-L2 inhibitor Substances 0.000 claims 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 206010038019 Rectal adenocarcinoma Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000034254 Squamous cell carcinoma of the cervix uteri Diseases 0.000 claims 1
- 206010041866 Squamous cell carcinoma of the vagina Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 1
- 201000002454 adrenal cortex cancer Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000002659 cell therapy Methods 0.000 claims 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 claims 1
- 201000010897 colon adenocarcinoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000030381 cutaneous melanoma Diseases 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000030173 low grade glioma Diseases 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 1
- 208000019420 lymphoid neoplasm Diseases 0.000 claims 1
- 208000025854 malignant tumor of adrenal cortex Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000010445 mica Substances 0.000 claims 1
- 229910052618 mica group Inorganic materials 0.000 claims 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 1
- 201000010302 ovarian serous cystadenocarcinoma Diseases 0.000 claims 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 1
- 201000010198 papillary carcinoma Diseases 0.000 claims 1
- 208000007312 paraganglioma Diseases 0.000 claims 1
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 1
- 229940121654 pd-l2 inhibitor Drugs 0.000 claims 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 claims 1
- 201000001281 rectum adenocarcinoma Diseases 0.000 claims 1
- 210000005132 reproductive cell Anatomy 0.000 claims 1
- 201000003708 skin melanoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000002381 testicular Effects 0.000 claims 1
- 210000000115 thoracic cavity Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 208000012991 uterine carcinoma Diseases 0.000 claims 1
- 201000001384 vagina sarcoma Diseases 0.000 claims 1
- 208000021153 vaginal squamous cell carcinoma Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024034926A JP2024053048A (ja) | 2018-05-21 | 2024-03-07 | 分子遺伝子シグネチャーとその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862674285P | 2018-05-21 | 2018-05-21 | |
| US62/674,285 | 2018-05-21 | ||
| US201862747853P | 2018-10-19 | 2018-10-19 | |
| US62/747,853 | 2018-10-19 | ||
| PCT/US2019/033052 WO2019226514A2 (en) | 2018-05-21 | 2019-05-20 | Molecular gene signatures and methods of using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024034926A Division JP2024053048A (ja) | 2018-05-21 | 2024-03-07 | 分子遺伝子シグネチャーとその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021524744A JP2021524744A (ja) | 2021-09-16 |
| JP2021524744A5 JP2021524744A5 (https=) | 2022-05-30 |
| JPWO2019226514A5 true JPWO2019226514A5 (https=) | 2022-05-30 |
Family
ID=67002367
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564841A Pending JP2021524744A (ja) | 2018-05-21 | 2019-05-20 | 分子遺伝子シグネチャーとその使用方法 |
| JP2024034926A Pending JP2024053048A (ja) | 2018-05-21 | 2024-03-07 | 分子遺伝子シグネチャーとその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024034926A Pending JP2024053048A (ja) | 2018-05-21 | 2024-03-07 | 分子遺伝子シグネチャーとその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210363590A1 (https=) |
| EP (1) | EP3797173A2 (https=) |
| JP (2) | JP2021524744A (https=) |
| CN (1) | CN112771177A (https=) |
| AU (1) | AU2019275404A1 (https=) |
| CA (1) | CA3100200A1 (https=) |
| WO (1) | WO2019226514A2 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210121016A (ko) * | 2018-12-21 | 2021-10-07 | 나노스트링 테크놀로지스, 인크. | 병리학적 표본의 모바일 디지털 공간 프로파일링을 위한 방법, 장치, 시스템 및 디바이스 |
| US20230062248A1 (en) * | 2020-01-31 | 2023-03-02 | Allarity Therapeutics Europe ApS | Methods for predicting ixabepilone responsiveness in cancer patients |
| ES2849965B2 (es) * | 2020-02-21 | 2023-11-17 | Fundacion Para La Investig E Innovacion Biosanitaria De Asturias Finba Ispa | Metodo para predecir o pronosticar la respuesta al tratamiento del cancer |
| WO2021228888A1 (en) * | 2020-05-12 | 2021-11-18 | Asylia Diagnostics | Biomarkers for hyperprogressive disease and therapy response after immunotherapy |
| US20230250173A1 (en) * | 2020-07-01 | 2023-08-10 | Pfizer Inc. | Biomarkers for pd-1 axis binding antagonist therapy |
| WO2022012420A1 (zh) * | 2020-07-17 | 2022-01-20 | 信达生物制药(苏州)有限公司 | 一种核苷酸组合及其应用 |
| US12263233B2 (en) * | 2020-10-19 | 2025-04-01 | Washington University | Compositions and methods for modulating Myc target protein 1 |
| TW202241469A (zh) * | 2021-02-20 | 2022-11-01 | 美商凱特製藥公司 | 免疫療法 |
| EP4302093A1 (en) * | 2021-03-01 | 2024-01-10 | Genentech, Inc. | Diagnostic methods and methods of treatment of ovarian cancer |
| WO2022211620A1 (en) * | 2021-04-01 | 2022-10-06 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Cd4/il-2 biomarker. |
| CN114231623B (zh) * | 2021-10-14 | 2023-09-08 | 福建中医药大学 | Palmdelphin在制备人结直肠癌检测及治疗产品中的应用 |
| WO2023070121A1 (en) * | 2021-10-22 | 2023-04-27 | The Wistar Institute Of Anatomy And Biology | Compositions and methods for treatment of mic60 depleted cancers and metastasis |
| CN113913507A (zh) * | 2021-10-29 | 2022-01-11 | 温州医科大学附属第一医院 | Ccl3蛋白作为评估非酒精性脂肪性肝病炎症水平及疾病进展的生物标志物的应用 |
| WO2023092119A2 (en) * | 2021-11-22 | 2023-05-25 | Ludwig Institute For Cancer Research Ltd | Methods for predicting responsiveness to a cancer therapy |
| US20230257825A1 (en) * | 2022-02-04 | 2023-08-17 | City Of Hope | Breast cancer biomarkers and methods of use |
| US20260002216A1 (en) * | 2022-02-18 | 2026-01-01 | London Health Sciences Centre Research Inc. | Immune Classification Tool for Determining Survival Outcomes in Cancer |
| CN115896290B (zh) * | 2022-11-29 | 2023-11-24 | 中国人民解放军海军军医大学 | Trim21基因检测在肿瘤诊断、治疗选择和预后评估中的应用 |
| WO2024227553A1 (en) * | 2023-05-01 | 2024-11-07 | The Chancellor, Masters And Scholars Of The University Of Oxford | Biomarkers for use in cancer treatment and predicting responsiveness to a cancer therapy |
| WO2024234348A1 (en) * | 2023-05-17 | 2024-11-21 | Yanjun Wang | Biomarker for immune checkpoint blockade therapy in nsclc |
| CN119685476A (zh) * | 2024-05-29 | 2025-03-25 | 深圳湾实验室 | 一种与癌症预后相关的基因标志物及其应用 |
| CN120775978A (zh) * | 2025-03-14 | 2025-10-14 | 浙江省肿瘤医院 | 乳头状甲状腺癌早期预测标志物的筛选方法及应用 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| EP0491007B1 (en) | 1989-09-08 | 1996-03-13 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| EP0659439B1 (en) | 1993-12-24 | 2001-10-24 | MERCK PATENT GmbH | Immunoconjugates |
| US5679683A (en) | 1994-01-25 | 1997-10-21 | Warner-Lambert Company | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| MX9707453A (es) | 1995-03-30 | 1997-12-31 | Pfizer | Derivados de quinazolina. |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508537D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
| MX9800215A (es) | 1995-07-06 | 1998-03-31 | Novartis Ag | Pirrolopirimidas y procesos para su preparacion. |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| HU228446B1 (en) | 1996-04-12 | 2013-03-28 | Warner Lambert Co | Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof |
| ID19609A (id) | 1996-07-13 | 1998-07-23 | Glaxo Group Ltd | Senyawa-senyawa heterosiklik |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| ATE241986T1 (de) | 1997-05-06 | 2003-06-15 | Wyeth Corp | Verwendung von chinazolin verbindungen zur behandlung von polyzystischer nierenkrankheit |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| CN1278176A (zh) | 1997-11-06 | 2000-12-27 | 美国氰胺公司 | 喹唑啉衍生物作为用于治疗结肠息肉的酪氨酸激酶抑制剂的应用 |
| WO2000031048A1 (en) | 1998-11-19 | 2000-06-02 | Warner-Lambert Company | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases |
| US7473767B2 (en) | 2001-07-03 | 2009-01-06 | The Institute For Systems Biology | Methods for detection and quantification of analytes in complex mixtures |
| AU2003221684A1 (en) | 2002-04-08 | 2003-10-27 | Smithkline Beecham Corporation | Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor |
| CN1852974A (zh) * | 2003-06-09 | 2006-10-25 | 密歇根大学董事会 | 用于治疗和诊断癌症的组合物和方法 |
| WO2005071419A2 (en) * | 2004-01-16 | 2005-08-04 | Ipsogen | Protein expression profiling and breast cancer prognosis |
| EP1930414B1 (en) * | 2005-09-08 | 2012-07-18 | Medinet Co., Ltd. | Method for activation treatment of antigen-presenting cell |
| US8986926B2 (en) | 2005-12-23 | 2015-03-24 | Nanostring Technologies, Inc. | Compositions comprising oriented, immobilized macromolecules and methods for their preparation |
| EP1963531B1 (en) | 2005-12-23 | 2011-09-21 | Nanostring Technologies, Inc. | Nanoreporters and methods of manufacturing and use thereof |
| JP5081232B2 (ja) | 2006-05-22 | 2012-11-28 | ナノストリング テクノロジーズ， インコーポレイテッド | ナノレポーターを分析するためのシステムおよび方法 |
| US20090076734A1 (en) * | 2007-03-22 | 2009-03-19 | Torres-Roca Javier F | Gene Signature for the Prediction of Radiation Therapy Response |
| US8415102B2 (en) | 2007-04-10 | 2013-04-09 | Nanostring Technologies, Inc. | Methods and computer systems for identifying target-specific sequences for use in nanoreporters |
| US8519115B2 (en) | 2008-08-14 | 2013-08-27 | Nanostring Technologies, Inc. | Stable nanoreporters |
| WO2010076788A2 (en) * | 2008-12-29 | 2010-07-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection |
| WO2011047087A2 (en) | 2009-10-13 | 2011-04-21 | Nanostring Technologies, Inc. | Protein detection via nanoreporters |
| WO2012129488A2 (en) * | 2011-03-23 | 2012-09-27 | Virginia Commonwealth University | Gene signatures associated with rejection or recurrence of cancer |
| GB201217892D0 (en) | 2012-10-05 | 2012-11-21 | Virttu Biolog Ltd | Treatment of cancer |
| SG11201502778TA (en) * | 2012-10-12 | 2015-05-28 | Agency Science Tech & Res | Method of prognosis and stratification of ovarian cancer |
| AU2014278152A1 (en) | 2013-06-14 | 2015-12-24 | Nanostring Technologies, Inc. | Multiplexable tag-based reporter system |
| WO2016044189A1 (en) * | 2014-09-15 | 2016-03-24 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists |
| WO2016049276A1 (en) * | 2014-09-25 | 2016-03-31 | Moffitt Genetics Corporation | Prognostic tumor biomarkers |
| EP3230498B1 (en) * | 2014-12-09 | 2023-01-18 | Merck Sharp & Dohme LLC | System and methods for deriving gene signature biomarkers of response to pd-1 antagonists |
| JP2018503373A (ja) * | 2014-12-30 | 2018-02-08 | ジェネンテック， インコーポレイテッド | がんの予後診断及び治療のための方法及び組成物 |
| RS61152B2 (sr) * | 2015-05-12 | 2024-06-28 | Hoffmann La Roche | Terapeutski i dijagnostički postupci za lečenje raka |
| WO2017015099A1 (en) | 2015-07-17 | 2017-01-26 | Nanostring Technologies, Inc. | Simultaneous quantification of gene expression in a user-defined region of a cross-sectioned tissue |
| WO2017096458A1 (en) * | 2015-12-07 | 2017-06-15 | Ontario Institute For Cancer Research (Oicr) | Immune gene signature predictive of anthracycline benefit |
| WO2017216559A1 (en) * | 2016-06-14 | 2017-12-21 | Almac Diagnostics Limited | Predicting responsiveness to therapy in prostate cancer |
| CA3040194A1 (en) * | 2016-10-13 | 2018-04-19 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for predicting response and resistance to ctla4 blockade in melanoma using a gene expression signature |
| EP3622092A4 (en) * | 2017-05-11 | 2021-06-23 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF |
| JP2021521439A (ja) * | 2018-04-13 | 2021-08-26 | エックス４ ファーマシューティカルズ， インコーポレイテッド | がん血清バイオマーカーおよびその使用方法 |
-
2019
- 2019-05-20 CN CN201980048546.5A patent/CN112771177A/zh active Pending
- 2019-05-20 CA CA3100200A patent/CA3100200A1/en active Pending
- 2019-05-20 WO PCT/US2019/033052 patent/WO2019226514A2/en not_active Ceased
- 2019-05-20 AU AU2019275404A patent/AU2019275404A1/en not_active Abandoned
- 2019-05-20 EP EP19732785.1A patent/EP3797173A2/en not_active Withdrawn
- 2019-05-20 US US17/054,204 patent/US20210363590A1/en not_active Abandoned
- 2019-05-20 JP JP2020564841A patent/JP2021524744A/ja active Pending
-
2024
- 2024-03-07 JP JP2024034926A patent/JP2024053048A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021524744A5 (https=) | ||
| JPWO2019226514A5 (https=) | ||
| Tu et al. | Assessment of the expression of the immune checkpoint molecules PD‐1, CTLA4, TIM‐3 and LAG‐3 across different cancers in relation to treatment response, tumor‐infiltrating immune cells and survival | |
| US11970745B2 (en) | Method for assessing a prognosis and predicting a response of patients with malignant diseases to immunotherapy | |
| Guibert et al. | Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma | |
| Choueiri et al. | Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial | |
| Hernandez et al. | Expression of the antiapoptotic protein survivin in colon cancer | |
| Straub et al. | CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity | |
| Chaudhry et al. | Resistance to chemotherapy and hormone therapy in endometrial cancer | |
| Wang et al. | Association between Tim‑3 and Gal‑9 expression and gastric cancer prognosis | |
| Lunghi et al. | The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting | |
| US20140155397A1 (en) | Emt signatures and predictive markers and method of using the same | |
| Mahmoudian et al. | Correlation between the immune checkpoints and EMT genes proposes potential prognostic and therapeutic targets in ESCC | |
| Li et al. | Follistatin-like 1 (FSTL1) is a prognostic biomarker and correlated with immune cell infiltration in gastric cancer | |
| Yao et al. | Pan-cancer biomarkers: changing the landscape of molecular testing | |
| JP2020533293A5 (https=) | ||
| Wu et al. | TOPK promotes the growth of esophageal cancer in vitro and in vivo by enhancing YB1/eEF1A1 signal pathway | |
| Zhang et al. | Establishment of the prognostic index of lung squamous cell carcinoma based on immunogenomic landscape analysis | |
| Ghasemian et al. | Long noncoding RNA LINC00978 acts as a potential diagnostic biomarker in patients with colorectal cancer | |
| Liao et al. | Diagnostic, prognostic, and immunological roles of CD177 in cervical cancer | |
| US11685955B2 (en) | Method for predicting response of patients with malignant diseases to immunotherapy | |
| Robinson et al. | Analysis of the progression of cervical cancer in a low-and-middle-income country: from pre-malignancy to invasive disease | |
| Qiu et al. | DEPP1: A prognostic biomarker linked to stroma-rich and immunosuppressive microenvironment, promoting oxaliplatin resistance in gastric cancer | |
| Yang et al. | Identification of TAP2 as a novel immune target in human cancers: insights from integrated bioinformatics and experimental approaches | |
| Jiang et al. | Characterization of SHCBP1 to prognosis and immunological landscape in pan-cancer: novel insights to biomarker and therapeutic targets |